BioNexus Gene Lab Corp financial data

Symbol
BGLC on Nasdaq
Location
Kuala Lumpur, Malaysia
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 437% % -13%
Quick Ratio 81% % 7%
Debt-to-equity 21% % 20%
Return On Equity -30% % -204%
Return On Assets -25% % -195%
Operating Margin -25% % -155%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,796,597 shares
Common Stock, Shares, Outstanding 1,796,597 shares -90%
Entity Public Float $8,160,000 USD -88%
Common Stock, Value, Issued $17,331,810 USD -0%
Weighted Average Number of Shares Outstanding, Diluted 1,796,597 shares -0.01%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $9,465,006 USD 2.2%
Cost of Revenue $8,066,572 USD 0.67%
Research and Development Expense $56,968 USD 42%
Selling and Marketing Expense $2,195,554 USD -56%
General and Administrative Expense $1,661,289 USD -44%
Operating Income (Loss) $2,348,440 USD -161%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $2,370,522 USD -158%
Income Tax Expense (Benefit) $40,565 USD 33%
Net Income (Loss) Attributable to Parent $2,296,809 USD -144%
Earnings Per Share, Diluted 0 USD/shares 47%

Balance Sheet

Label TTM Value / Value Unit Change %
Accounts Receivable, after Allowance for Credit Loss, Current $1,522,158 USD
Inventory, Net $1,007,448 USD -27%
Assets, Current $5,626,802 USD -20%
Property, Plant and Equipment, Net $1,570,584 USD -9.1%
Operating Lease, Right-of-Use Asset $186,082 USD -20%
Assets $7,621,228 USD -31%
Accounts Payable, Current $1,182,723 USD -17%
Liabilities, Current $678,023 USD -52%
Deferred Income Tax Liabilities, Net $0 USD -100%
Operating Lease, Liability, Noncurrent $126,943 USD -29%
Liabilities $804,966 USD -50%
Accumulated Other Comprehensive Income (Loss), Net of Tax $112,547 USD 31%
Retained Earnings (Accumulated Deficit) $5,391,110 USD -74%
Stockholders' Equity Attributable to Parent $6,816,262 USD -27%
Liabilities and Equity $7,621,228 USD -31%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $824,072 USD -2118%
Net Cash Provided by (Used in) Financing Activities $860 USD -103%
Net Cash Provided by (Used in) Investing Activities $15,646 USD -529%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 1,796,597 shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $797,528 USD -909%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $1,153,121 USD -72%
Interest Paid, Excluding Capitalized Interest, Operating Activities $1,545 USD -43%
Operating Lease, Liability $183,746 USD 625%
Depreciation $26,642 USD 32%
Payments to Acquire Property, Plant, and Equipment $9,052 USD -59%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $2,571,406 USD -12295%
Property, Plant and Equipment, Gross $2,541,732 USD 1.5%
Operating Lease, Liability, Current $56,803 USD 18%
Preferred Stock, Shares Authorized 30,000,000 shares 0%
Additional Paid in Capital $5,011,891 USD 0%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years $66,940 USD
Operating Leases, Future Minimum Payments Due, Next Twelve Months $0 USD
Operating Leases, Future Minimum Payments, Due in Three Years $60,261 USD
Operating Leases, Future Minimum Payments Due $203,634 USD
Interest Expense $6,193 USD 45%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares